Hanna Bandos

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

Andrew Tutt, Judy E. Garber, Bella Kaufman et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

André Robidoux, Gong Tang, Priya Rastogi et al. · The Lancet Oncology · 2013 · 382 citations

Breast Oncology, Neoadjuvant Therapy, Medicine +7

NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).

Steven J. Chmura, Kathryn Winter, Wendy A. Woodward et al. · Journal of Clinical Oncology · 2022 · 188 citations

Surgical Oncology, Breast Oncology, Cancer Management +19

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial

Eleftherios P. Mamounas, Hanna Bandos, Barry C. Lembersky et al. · The Lancet Oncology · 2018 · 158 citations · Full text

Postmenopausal Breast Cancer, Oncology, Breast Oncology +12

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30

Hanna Bandos, Joy Melnikow, Donna R. Rivera et al. · JNCI Journal of the National Cancer Institute · 2017 · 124 citations · Full text